Partnering Hall Speakers Agenda Overview WSGR website
2017 Speakers

 

Edward Andrle
LivaNova PLC

Meneesh Arora
Exact Sciences Corporation

Todd Brinton
Stanford University

Daniel Burnett
TheraNova LLC

David Cassak
The MedTech Strategist 

Andrew Cleeland
Fogarty Institute for Innovation (FII)

Jed Cohen
Leerink Partners

Mark Deem
The Foundry

Eugene de Juan
ForSight Labs

Michael DeMane
Nevro Corp.

Andrew ElBardissi
Deerfield Capital

Vera Elson
Wilson Sonsini Goodrich & Rosati

Jeff Farkas
Medtronic

William Farrell, Jr.
Longford Capital Management, LP

Rob Faulkner
Redmile Group

Octavian Florescu
Xip

Farah Gerdes
Wilson Sonsini Goodrich & Rosati

Paul Grand
MedTech Innovator

Kenichi "Ken" Hata
Terumo Corporation

James Heslin
Wilson Sonsini Goodrich & Rosati

Jo Carol Hiatt
Kaiser Permanente

David Hoffmeister
Wilson Sonsini Goodrich & Rosati

David Hovda
Simplify Medical

Beverly Huss
Qool Therapeutics

Masazumi "Masa" Ishii
AZCA, Inc

Yue-Teh Jang
Medeon Biodesign, Inc.

Kewen Jin
Serica Partners

Kevin King
iRhythm Technologies, Inc.

Amy Len Kobe
Baxter Ventures

Jeffie Kopczynski
Medtronic

Anne Kopf-Sill
Stanford University

Jennifer Kozak
Johnson & Johnson

Uday Kumar
Element Science

 

* Invited


 

Mark Leahey
Medical Device Manufacturers Association (MDMA)

Christopher Letang
SRS Acquiom

Angela Macfarlane
ForSight Labs

Donald May
AdvaMed

Casey McGlynn
Wilson Sonsini Goodrich & Rosati

Eric Milledge
Endeavor Vision SA

Trevor Moody
M.H. Carnegie & Company

Jack Moorman
US-Japan MedTech Frontiers (USJMF)

Yuichiro Morimoto
Enplas Corporation

Scott Murano
Wilson Sonsini Goodrich & Rosati

Reza Naima
ReThink Medical

Sara Nakashima
Stanford University

Evan Norton
Abbott Ventures, Inc.

Phil Oettinger
Wilson Sonsini Goodrich & Rosati

Richard "Rick" Packer
Asahi Kasei/ZOLL Medical Corporation

Jenell Paul-Robinson
MedTech Innovator

Donna Petkanics
Wilson Sonsini Goodrich & Rosati

Doug Portnow
Wilson Sonsini Goodrich & Rosati

Praveen Raja
Amgen

Leighton Read
Brandon Capital Partners

Duke Rohlen
Spirox, Inc.

Elton Satusky
Wilson Sonsini Goodrich & Rosati

Valeska Schroeder
KCK Group

Daniel Sheehan
Medtronic

John Shimmick
Wilson Sonsini Goodrich & Rosati

Sarah Sorrel
Medpass International

Arthur Taylor
Transcend Medical, Inc.

Fred Toney
Launchpad Digital Health

Gwen Watanabe
Teleflex Inc.

Martin Waters
Wilson Sonsini Goodrich & Rosati

Jay Watkins
Curation Capital

Norman Weldon
Partisan Management Group, Inc.

[ Back to top ]

Speakers Biographies

 

Edward S. Andrle
Senior Vice President, New Ventures & Business Development, LivaNova PLC

Edward S. Andrle is Senior Vice President of Business Development and New Ventures for LivaNova PLC. His team played an important role in the $2.7 billion merger of Sorin Group and Cyberonics to form LivaNova PLC in October, 2015. Mr Andrle joined Sorin Group in 2010 and his group subsequently spearheaded investments in, or acquisitions of, six companies in the heart failure, sleep apnea and percutaneous mitral valve markets. He also manages Sorin’s New Ventures group which manages and develops these early stage programs. He is currently a Board member of Respicardia, Highlife, MD Start and Enopace.

Prior to Sorin, Mr. Andrle co-founded, developed, and sold three medical device companies in the Minneapolis area. TERAMED was focused on an endovascular system to treat abdominal aortic aneurysms and was acquired by Johnson&Johnson. Myocor developed an implantable device to treat mitral valve regurgitation and was acquired by Edwards. And StarFire Medical developed technology to treat brain aneurysms and was acquired by NFocus Neuromedical (Covidien).

Mr. Andrle also spent five years as a Vice President of Boston Scientific. Mr. Andrle lead a new business unit that developed a number of peripheral vascular catheters and guidewires that eventually accounted for over $100 million in sales for Boston Scientific. He has an MBA from the Stanford Graduate School of Business and a BS in Chemical Engineering from the University of Notre Dame.

[ Back to top ]

Maneesh Arora
CEO, Exact Sciences Corporation

Maneesh Arora has been the chief operating officer of Exact Sciences Corporation since February 2012, as well as the senior vice president since April 2009. Mr. Arora also served as the chief financial officer from April 2009 to August 2013. Prior to joining Exact, Mr. Arora worked for Third Wave Technologies, Inc., a molecular diagnostics company, until the acquisition of Third Wave by Hologic, Inc. in July 2008. During his time at Third Wave, Mr. Arora was responsible for business strategy and commercial operations before being promoted to chief financial officer in January 2006. He began his career at Kraft Foods as a financial analyst and held several positions of increasing responsibility during his nine years there. Mr. Arora earned a bachelor's degree in economics from the University of Chicago and an MBA from the Kellogg Graduate School of Management at Northwestern University.

[ Back to top ]

Todd Brinton
Clinical Professor, Medicine (Cardiology), Adjunct Professor, Bioengineering, Stanford University

Dr. Brinton is a Clinical Professor of Medicine (Cardiology) and Adjunct Professor of Bioengineering at Stanford University. He is an attending interventional cardiologist at both Stanford University Medical Center and the Palo Alto VA Medical Center. He has served as the fellowship director for the Stanford Byers Center for Biodesign since 2005 and also co-directs both the executive education program in innovation management and the graduate course series in biodesign innovation at Stanford.

Dr. Brinton lectures on strategies for innovation and serves as a mentor to innovation fellows, graduate students, and healthcare executives. His academic research focuses on the process of innovation for development of novel medical technologies. He specifically focuses on the integration of research and development for new technologies with the clinical strategy and pre-clinical evaluation. His primary clinical interest is the treatment of complex coronary disease and he has served as a clinical investigator for several studies of interventional-based therapies for ischemia heart disease and heart failure.

Dr. Brinton completed his medicine, cardiology, and interventional cardiology training at Stanford University. He holds an MD from the Chicago Medical School and a BS in Bioengineering from the University of California, San Diego. He is co-founder and board director for Shockwave Medical and BioParadox, Inc., which are both venture-backed medical device companies in the cardiovascular space. He served on the board of directors of Infogard Laboratories prior to acquisition. In addition, he serves on the advisory board of a number of early-stage medical device companies where he focuses on clinical development and strategy. Prior to medical school he was the Clinical Research Director for Pulse Metric, Inc., a venture-backed medical device start-up company.

[ Back to top ]

Daniel Burnett
Managing Partner, TheraNova LLC

Dr. Burnett received his M.D. and M.B.A. degrees from Duke University and completed his residency at the Mayo Clinic.  He has worked briefly at the FDA and was a General Partner at a medical device focused venture capital firm from 2003-05. Dr. Burnett holds a medical license in California and he is an Associate Professor in the Department of Bioengineering at UCSF where he also acts as Industry Director for the Masters of Translational Medicine program. Since 2006 he has founded nine TheraNova spinouts which have collectively raised over $250M in capital.

In addition to his commercial efforts Dr. Burnett has been very active in the nonprofit community.  He has volunteered at the Haight Ashbury Free Clinic, participated in medical missions to Central America and formed two nonprofits, one to design medical devices for low to middle income countries (LMIC) and one to send unused supplies to LMICs.

[ Back to top ]

2David Cassak
Editor-In-Chief, The MedTech Strategist

David Cassak has more than 30 years of experience in the health care industry. Prior to co-founding Innovation In Medtech, LLC, he served as Vice President, Content and Managing Director, Medical Devices for Elsevier Business Intelligence, A Reed Elsevier Company, now part of Informa Business Information, where he wrote extensively on the medical device industry for Windhover’s monthly publications, IN VIVO and START-UP. He is also a frequent speaker before various companies and industry trade groups. Prior to joining Elsevier, Cassak worked for nearly 20 years at Windhover Information Inc., a company he founded with his partner, Roger Longman, which spun out the publications business of The Wilkerson Group, a leading management consulting firm at the time. Long known for publishing IN VIVO, widely recognized as the premier provider of business intelligence in the health care industry, Windhover launched a number of other successful publications, including START-UP: Emerging Medical Ventures, and The RPM Report: Regulation • Policy • Market Access. In 2004, Windhover acquired Medtech Insight, Inc., which published the MEDTECH INSIGHT: Medical Technology Market Intelligence newsletter. While at Windhover/EBI, David also organized and produced numerous conferences around the world, including the Investment in Innovation (In3) medical device partnering conference series, as well as such pharma-focused conferences as Pharmaceutical Strategic Alliances, Euro-Biotech and BIO-Windhover. In 2008, Windhover was acquired by Elsevier, which formed Elsevier Business Intelligence, combining the products of Windhover and F-D-C Reports, publishers of The Gray Sheet and The Pink Sheet, among other industry newsletters.

[ Back to top ]

2Andrew Cleeland
President, Fogarty Institute for Innovation (FII)

Andrew Cleeland is the President of the Fogarty Institute for Innovation (FII), a nonprofit institution located on the El Camino Hospital campus in Mountain View and focuses on providing entrepreneurs working on promising new medical therapies mentorship and access to expert intellectual, physical and financial resources to propel medical concepts from initiation to application.  Prior to joining FII, Andrew worked at Medtronic following the acquisition of Twelve Inc. Prior to Twelve, he was the president and CEO of Ardian, the pioneer of renal denervation for hypertension, heart failure and other associated disorders. Medtronic acquired Ardian in 2011 in one of the largest venture-funded exits in medtech history.

[ Back to top ]

2Jed Cohen
Managing Director, Leerink Partners

Jed Cohen joined Leerink Partners as a Managing Director in 2009 to cover the medical technology sector. Jed has 23 years of Healthcare Investment Banking experience, including 12 years at Citigroup and three years at UBS prior to joining Leerink. Jed’s transaction experience includes advisory work and financing assignments with clients across the healthcare industry, with an exclusive focus on “middle market” / emerging growth segments of the medical technology industry since 2000. He received a Bachelor of Science in Economics from the University of Pennsylvania’s Wharton School.

[ Back to top ]

2Kevin Conroy
Chairman of the Board, CEO and President, Exact Sciences Corporation

Kevin Conroy is chairman of the board, and chief executive officer and president of Exact Sciences Corporation. Since 2009, Kevin oversees the company’s strategy in cooperation with the board and investors, creates and fosters a culture of collaboration and innovation, builds a strong leadership team and ensures company resources are properly allocated to create the most value.

Previously, Kevin was chief executive officer and president of Third Wave Technologies, intellectual property counsel at GE Healthcare, chief operating officer of venture-backed technology companies, intellectual property litigator at McDermott Will & Emory, and partner at Pattishall, McAuliffe, Newbury, Hilliard and Geraldson.

[ Back to top ]

2Mark Deem
Managing Partner, The Foundry, LLC

Mark Deem joined The Foundry at its inception in 1998. In addition to spearheading the research and invention process on new clinical opportunities, Mr. Deem leads the early stage effort in The Foundry's new companies until the company's CEO and Senior Staff is hired.

Prior to joining The Foundry, Mr. Deem worked in various research and development roles with Ventrica, Micro-Interventional Systems, Devices for Vascular Intervention, Cordis Corporation and the USCI Division of C.R. Bard.

Mr. Deem has spent over twenty-five years in the design, testing and manufacture of medical devices. He is a co-inventor on over 150 issued and pending U.S. patents. Mark earned his B.S. degree in biomedical engineering from Boston University.

Mark serves as a Director for FIRE1, Holaira, Twelve, as Chairman of Miramar Labs, and as a Venture Partner with Lightstone Ventures.

[ Back to top ]

Eugene de Juan
Managing Member, ForSight Labs

Renowned retinal surgeon, inventor, and entrepreneur Dr. Eugene de Juan, Jr., serves as Managing Member of ForSight Labs, where he participates as an active inventor and advisor in early-stage ophthalmic opportunities.

Dr. de Juan, Jr. splits his time between ForSight Labs and UCSF. He holds the "Jean Kelly Stock Distinguished Chair" in Ophthalmology. UCSF recruited Dr. de Juan for this special role to augment translation of the many ideas being developed within the academic center. He continues to see patients and teach at UCSF.

Dr. de Juan, Jr., has participated in the development of a number of ophthalmology’s most exciting technologies with over 100 products and founding 10 venture funded companies, including Second Sight, InnoRx (bought by Surmodics in 2005), and NeoVista, Inc., in addition to ForSight Labs’ six companies since 2005 of which 4 have sold (Novartis, Allergan, Roche, and QLT) and the other two under strategic partnerships.

Prior to moving to San Francisco, Dr. de Juan, Jr., was a professor of ophthalmology at the University of Southern California and chief executive officer of the Doheny Retina Institute, focusing on advanced surgical techniques for treating blinding retinal disorders through retinal transplantation, macular translocation, robotic surgery, retinal implants and other new procedures, medicines and instruments.

Prior to these positions, Dr. de Juan served at the Wilmer Eye Institute at Johns Hopkins University School of Medicine, where he was co-director of Vitreoretinal Service, director of the Microsurgery Advanced Design Laboratory (MADLAB) and Joseph E. Green Professor of Ophthalmology. From 1983 to 1992 he was a member of the medical staff of the Duke University Eye Center, holding joint teaching appointments with the departments of ophthalmology and cell biology.

He is a loyal supporter of ophthalmic education and development and established a chair for Ophthalmic Education at Johns Hopkins University.

Dr. de Juan completed his medical degree and internship training at the University of South Alabama College of Medicine. He served an internship at University of South Alabama Medical Center followed by a residency at the Wilmer Ophthalmological
Institute in Baltimore, Maryland, and a fellowship in vitreoretinal surgery at Duke University. He holds patents on over 130 inventions and has 250 academic publications.

[ Back to top ]

Michael DeMane
Chairman, Nevro Corp.

Michael DeMane is Chairman of the Board of Nevro (NVRO), a Silicon Valley based leader in the medical device field. Michael led the company as Chief Executive Officer from March 2011 until June, 2016, from scrappy start-up to a leading global player in the spinal cord stimulation market.

With an emphasis on the strategy and culture of growth businesses, under his leadership the company, raised two venture funding rounds totaling $106M, completed a $145M IPO, initiated a public follow-on offering which was upsized to $260M, and instilled a focus on level one clinical evidence and patient outcomes that transformed the global SCS market.

An engineer by training, Michael has established a consistent record of strategic and operational success leading large and mid-size global med-tech organizations. Over the past 35 years, he has held executive leadership roles in the US, Europe and Australasia.

Prior to Nevro, Michael held a variety of positions at Medtronic, Inc., including: Chief Operating Officer, Sr. VP and President Europe, Canada, Latin America and Emerging Markets, and Sr. VP and President Spinal, ENT, and Navigation. In each of these roles he served on Medtronic's Executive Committee. Before joining Medtronic, Michael served as Managing Director, Australasia for Smith & Nephew Pty. Ltd.

Michael has served as a senior advisor to Thomas McNerney & Partners, and Oak Hill Capital and serves on several Boards of Directors including: Cardionomic, Rotation Medical, and Safe Orthopaedics.

Michael has completed the Advanced Management Program at INSEAD in Fontainebleau, France and holds an M.S. in Bioengineering from Clemson University and a B.S in Chemistry from St. Lawrence University in Canton, New York.

[ Back to top ]

2Andrew ElBardissi
Principal, Deerfield Capital

Andrew ElBardissi is a Principal at Deerfield Capital. He focuses on investments in medical devices. Prior to joining Deerfield, Dr ElBardissi was at Longitude Capital focused on medical device venture investments and J.P. Morgan’s Healthcare Investment Banking practice focused on strategic Healthcare M&A as well as equity and debt issuances. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School, and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University. He received residency training in General Surgery at Harvard Medical School's Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ), has over 30 publications in leading peer reviewed scientific journals, and has presented his research at numerous medical and surgical conferences.

[ Back to top ]

Vera Elson
Partner, Wilson Sonsini Goodrich & Rosati

Vera M. Elson is a partner and trial lawyer based in Wilson Sonsini Goodrich & Rosati's Palo Alto office. Her practice is focused on intellectual property trials and strategic counseling for high technology clients.

She primarily handles patent cases in federal district courts across the country and proceedings before the International Trade Commission. She has extensive trial experience in high-stakes cases, including both jury trials and bench trials. Vera has also successfully litigated cases related to trade secret misappropriation, common law, and copyright claims. She has argued and won before the U.S. Court of Appeals for the Federal Circuit. She is registered to practice before the U.S. Patent and Trademark Office. Early in her career, she was an intern for the late Chief Judge Helen W. Nies of the U.S. Court of Appeals for the Federal Circuit. Prior to law school, Vera worked as an electrical engineer doing high-speed circuit design.

[ Back to top ]

Jeff Farkas
Vice President, Health Policy, Reimbursement and Health Economics, Medtronic

Jeff Farkas is Vice President, Health Policy, Reimbursement, and Health Economics, at Medtronic. In this role, Mr. Farkas coordinates the company’s strategies on health policy and reimbursement, leads Medtronic’s interactions with the Centers for Medicare and Medicaid Services (CMS) in the US, and supports Medtronic business units and global geographies on priority reimbursement and policy issues.  

Prior to joining Medtronic in 2002, Mr. Farkas served in the White House Office of Management and Budget from 1994 to 2001, culminating as Acting Chief of Health Financing, where he provided budget and policy recommendations to senior Administration officials and supervised a team of 10 analysts to oversee the $300+ billion budget of the Centers for Medicare and Medicaid Services (then the Health Care Financing Administration), including Medicare, Medicaid, the State Children’s Health Insurance Program, and CMS  program management.

Originally from Kings Park, New York, Mr. Farkas graduated from the University of Rochester with a BA in Political Science and an MS in Public Policy Analysis.

[ Back to top ]

William Farrell, Jr.
Managing Director and General Counsel

William P. Farrell, Jr. is a founder and managing director and general counsel of Longford Capital, a leading private investment company in the commercial litigation finance industry.  Bill is responsible for sourcing, underwriting and monitoring investments.  Bill serves on Longford Capital’s investment committee.

Bill is an experienced trial lawyer with more than 20 years of litigation and trial experience as both a government prosecutor and as a partner in the commercial litigation departments of two prominent national law firms, Neal, Gerber & Eisenberg LLP and Gardner, Carton & Douglas LLP (n/k/a Drinker, Biddle & Reath LLP).  He has served as the lead attorney in dozens of cases and taken numerous cases through trial and appeal.  He has negotiated and structured numerous settlements involving companies of all sizes.  As a result of Bill’s trial and appellate experience companies have relied on Bill for assistance in all aspects of complex commercial disputes from inception through settlement, trial, and appeal.  Bill has represented clients in state and federal courts and before arbitration panels and regulatory agencies.  His practice has included defense of antitrust claims and investigations, defense of class actions, healthcare litigation, intellectual property and trade secret litigation, First Amendment and defamation cases, consumer and commercial fraud, and a variety of contract and commercial disputes.

Before launching Longford Capital, Bill served as the outside general counsel to several companies and regularly provided advice to clients concerning litigation strategy, claim valuation, risk mitigation and avoidance, acquisitions, corporate structure, corporate governance, contracts, internal policies, and other issues.

Bill has been awarded the highest possible rating (AV Preeminent 5.0 out of 5.0) by the Martindale-Hubbell Peer Review Rating System for legal ability, expertise, experience, integrity and overall professional excellence.  Bill has been included in the 2015 and 2016 IAM Strategy 300 – The World’s Leading IP Strategists, an annual listing of individuals with an established track record in developing and implementing world class IP value creation programs.

Prior to entering private practice, Bill served as a prosecutor in the Criminal Prosecutions Bureau of the Cook County State’s Attorney’s Office.  As a government prosecutor, Bill served as the lead attorney in numerous trials and represented the State of Illinois in several cases before the Illinois Appellate Court.  Bill has also been appointed a Special Assistant Illinois Attorney General in connection with the representation of government officials and government agencies.

[ Back to top ]

Rob Faulkner
Managing Director, Redmile Group

Mr. Robert C. Faulkner, also known as Rob, serves as Managing Director of Redmile Group, LLC . Mr. Faulkner was a Research Analyst at Thomas Weisel Partners Equity Research. Mr. Faulkner was a Managing Director and Senior Research Analyst at JMP Securities LLC. He was also employed at JMP Securities LLC, Research Division. Mr. Faulkner joined JMP Securities LLC in April 2005 as a Managing Director and Senior Analyst covering the medical device industry. Prior to joining JMP Securities, Mr. Faulkner spent three years as a Senior Vice President and Senior Equity Analyst covering medical devices at Prudential Equity Group. He served as Equity Analyst of Prudential Equity Group, LLC, Research Division, J.P. Morgan H&Q Principals, LP, Research Division, JP Morgan Chase & Co, Research Division and Deutsche Bank AG, Research Division. From 1995 to 2001, Mr. Faulkner was a Managing Director and Senior Research Analyst at JPMorgan and its predecessor, Hambrecht & Quist, twice ranking first in a Greenwich Associates survey of small-cap medical device analysts. He served as a Vice President and Biotechnology Analyst at S.G. Warburg & Co. from 1992 to 1995 and previously worked as a consultant at The Wilkerson Group, assessing new healthcare technologies for healthcare product companies. Mr. Faulkner began his career in the healthcare industry at the SmithKline Beckman Corporation, where he served primarily in product management. He serves on the Board of Directors of Science 37. He has been a Director of Xeris Pharmaceuticals, Inc. since January 07, 2016. He holds an M.B.A. from the Amos Tuck School of Business at Dartmouth College and an A.B. from Harvard University.

[ Back to top ]

Octavian Florescu
CEO, Xip

Octavian Florescu is the CEO of Xip, a life science company applying digital integrated circuit technology to point of care (POC) diagnostics. Together with his team, he is now developing a heart attack marker assay platform that has clinical laboratory accuracy.

Prior to Xip, Octavian gained over 15 years of experience in the semiconductor field working with DEC, GE, Nokia, Quake Technologies and Qualcomm. He received a BS in Computer Engineering from the University of Waterloo, Canada, and a PhD in Electrical Engineering from the Berkeley Sensor & Actuator Center, Dept. of Electrical Engineering, University of California, with a minor in Molecular and Cell Biology.

[ Back to top ]

Farah Gerdes
Partner, Wilson Sonsini Goodrich & Rosati

Farah Gerdes is a partner in the technology transactions practice at Wilson Sonsini Goodrich & Rosati, where she focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in intellectual property transactions. She represents clients in a variety of domestic and international business transactions involving intellectual property or product rights, including intellectual property licenses, collaboration agreements, research and development agreements, clinical trial management, manufacturing agreements, supply and distribution agreements, university licenses, mergers and acquisitions, and the formation of joint ventures and other types of strategic alliances and partnering arrangements. As a complement to her transactional IP practice, Farah advises her life sciences clients on a variety of FDA regulatory and healthcare issues, such as strategies for obtaining FDA product approvals and clearances, fraud and abuse, compliance, HIPAA, and claims support for advertising and promotional materials.

[ Back to top ]

Paul Grand
CEO, MedTech Innovator

Paul is MedTech Innovator’s CEO. He founded and has managed MedTech Innovator as a program within RCT Ventures for the past four years. In 2016, with the financial support of RCT and other sponsors, Paul left to run MedTech Innovator as a stand-alone company. In his previous role as Managing Director for RCT Ventures, Grand was responsible for sourcing RCT’s investments in medical devices and representing RCT on the boards of its portfolio companies. He has extensive experience in new company formation and operations. Prior to joining RCT, Grand founded and operated eight high technology, medical device and biotechnology companies. In the life sciences, Grand was co-founder and VP of Operations of Imagine Pharmaceuticals and co-founder and CEO of MicroSurgeon in Los Angeles.

Grand is actively involved in programs to encourage bio-entrepreneurship, innovation and commercialization of University technologies. He is on the Oversight Committees for the Coulter Translational Research Partnership Programs at USC and University of Washington. Grand is a reviewer for proof of concept and commercialization-focused funding programs for the University of California system-wide, USC, University of Utah and University of Colorado.

Grand has spoken at more than 100 conferences, been featured in hundreds of articles in publications including Forbes, New York Times and Wall Street Journal and appeared as an expert on Bloomberg Television, CNN, and CNN/FN.

[ Back to top ]

Kenichi "Ken" Hata
General Manager, Business Development, Terumo Corporation

Ken Hata joined Terumo Corporation in 1994. As a global corporation with Japanese origins, Terumo focuses on growing segments while leveraging leading position in Japan to live up to its corporate mission of “Contributing to Society through Healthcare”. With a goal of enhancing its pipeline, bringing in technologies from outside and extending company’s horizons beyond the typical near- and mid-term perspectives, Ken has been in Silicon Valley actively leading the corporate venturing efforts since 2013 when Terumo became an LP of Emergent Medical Partners (Dr. Thomas J. Fogarty’s VC fund) aiming to play a role in the ecosystem. Ken holds an MBA degree from the Ross School of Business, University of Michigan.

[ Back to top ]

James Heslin
Partner, Wilson Sonsini Goodrich & Rosati

For more than 20 years, James Heslin has focused on helping medical device companies protect and enforce their domestic and international intellectual property rights, as well as advising venture capitalists who invest in medical technology companies. Jim's medical and surgical device clients span a broad array of technologies, including angioplasty, atherectomy, stent delivery, arthroscopic treatments, suturing devices, ultrasound imaging and therapy, gynecological devices, minimally invasive surgical equipment, implantable hearing aids, drug delivery systems, orthodontics, orthopedics, and diagnostics.

In addition, Jim has extensive experience in investor due diligence, portfolio evaluation, licensing matters, and the preparation of patent validity and infringement opinions. He also counsels clients regarding in-house intellectual property protection programs.

Prior to joining the firm, Jim was the founder and leader of the medical device technology patent group at Townsend and Townsend and Crew (now Kilpatrick Townsend). He also served as general counsel for Align Technology.

Jim currently serves as a member of the firm's Policy Committee.

[ Back to top ]

Jo Carol Hiatt
Chair, National Product Council, Kaiser Permanente

Jo Carol Hiatt, MD is Chair of the National Product Council for Kaiser Permanente (KP) and also chairs KP's Inter-Regional New Technologies Committee.  She is a partner in Southern California Permanente Medical Group (SCPMG) and is currently Assistant Medical Director, SCPMG Business Management.  Dr. Hiatt chairs Southern California's Medical Technology Deployment Strategy Team as well as the Oversight Committee for Integrated Medical Imaging.

Dr. Hiatt joined Kaiser Permanente as a general surgeon at Panorama City.  She subsequently served as Chief of Surgery at that location and was elected to the SCPMG Board of Directors.  Dr. Hiatt was appointed Regional Assistant Medical Director of Clinical Services, and has since assumed a number of regional and program-wide roles.  She served two terms on the Medicare Evidence Development & Coverage Advisory Committee. In 2013 she was designated an American College of Surgeons Health Policy Scholar. Dr. Hiatt was also a member of the National Medical Device Evaluation System Planning Board.

Dr. Hiatt received her undergraduate degree from Stanford University and her medical degree from Duke University.  She trained in general surgery at UCLA. In addition to her clinical degree, Dr. Hiatt received an MBA from UCLA's Anderson School of Management.  She presents internationally on KP’s technology assessment, selection, and implementation processes.

[ Back to top ]

David Hoffmeister
Partner, Wilson Sonsini Goodrich & Rosati

David Hoffmeister is a partner at Wilson Sonsini Goodrich & Rosati, where he plays a major leadership role in the firm's drug and device regulatory and healthcare law practice. David was named as one of the "25 Leading Biotech Attorneys" in California in 2011 by the Daily Journal, and is recognized as one of the leading food and drug regulatory lawyers in the country.

David brings more than 25 years of experience in drug and device regulatory and healthcare law to the firm. He represents pharmaceutical, biotechnology, medical device, diagnostic, and dietary supplement clients, advising them on a variety of regulatory and healthcare issues, such as strategies for obtaining FDA product approvals and clearances, recalls, labeling, and claim support for advertising and promotional materials. He has also conducted numerous internal investigations for pharmaceutical and medical device companies involving fraud and abuse, advertising and promotional practices, and clinical research practices.

Before joining Wilson Sonsini Goodrich & Rosati, David was senior counsel for drug and device law at Syntex U.S.A., Inc., where his primary focus was advising senior management on worldwide issues affecting the ability of the corporation and its affiliates to develop, manufacture, and distribute pharmaceutical, device, diagnostic, and over-the-counter drugs in compliance with the Federal Food, Drug, and Cosmetics Act, as well as implementing regulations and applicable state and federal healthcare laws.

[ Back to top ]

David Hovda
President & CEO, Simplify Medical

David Hovda has more than 20 years of experience in the medical device industry. Prior to joining Simplify Medical, he served as Vice President and Managing Director of the Spine and ENT divisions of ArthroCare, where he was responsible for the commercialization of numerous products and two business units. He also worked at Medtronic in corporate development and the corporate ventures group. David served as a Lieutenant in the United States Navy and completed two tours of duty. He received an M.B.A. from Harvard Graduate School of Business Administration and a B.S. in Civil Engineering from Northwestern University. He is an inventor on over thirty medical device patents, and serves on the board of Pro-Dex, Inc., where he is Chairman of the Audit Committee.

[ Back to top ]

Beverly Huss
President and CEO, Qool Therapeutics

Beverly Huss joined Qool Therapeutics as President and CEO in September 2013.  Previously, Beverly was President and CEO of Vibrynt, Inc. a company that developed a novel minimally invasive therapeutic device for treatment of morbid obesity.  Prior to this, Beverly was with Santa Clara, California-based Guidant since 1986, fulfilling a variety of executive roles within the company’s various medical device divisions. She managed the worldwide Endovascular Solutions business as President and quadrupled worldwide revenues to $150 million for the carotid and peripheral vascular business in four years.

Prior to this Beverly held several executive level positions as Vice President of Guidant’s Canada and Latin America operations, Vice President of Vascular Intervention Global Marketing and Vice President of the Stent Business Unit where she built the company’s coronary stent business, a market leader for 27 of 28 quarters. Earlier in her career, Beverly held engineering positions at both Honeywell Defense Systems Division and Jones and Laughlin Steel.  Additionally, she served as chairman of the Silicon Valley American Heart Association and as a senior advisor to Pervasis Therapeutics, a Cambridge, MA based cell therapy company.

Beverly holds a M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois. Beverly has several patents to her credit in the cardiovascular and obesity medical device areas. Beverly serves on the board of Surefire Medical, Ciel Medical, and the University of Illinois Material Science and Engineering steering Committee and Biomedical Engineering Steering Committee.  She previously served on the boards of Ulthera, Dade Behring, Inc., Wright Medical Inc., and Artes Medical.  She is a mentor in the Stanford University Biodesign Fellowship Program.  Beverly was the recipient of the 2013 University Of Illinois College Of Engineering Alumni Award for distinguished leadership in the medical device industry.

[ Back to top ]

Masazumi "Masa" Ishii
Managing Director, AZCA, Inc.

Mr. Masazumi (“Masa”) ISHII is a Managing Director of AZCA, Inc., a professional firm based in Menlo Park, California, which provides consulting and investment banking services to technology based companies to achieve their corporate development objectives in the Asia-Pacific markets.  Based on his thirty years of experience as a professional in international business and high technology, Mr. ISHII has supported numerous companies in North America, as well as Japan and other parts of Asia, in formulating and implementing their strategies on international businesses and new venture development. 

Mr. ISHII is also a Managing Director of AZCA Venture Partners, based in Menlo Park and San Diego.  AZCA Venture Partners Healthcare Fund is designed to help corporations aiming to strengthen their business in the Healthcare domain by means of strategic venture capital framework.  Prior to AZCA Venture Partners, he served as a Managing Director of Noventi, a VC firm based in Menlo Park, until 2015. Mr. ISHII has many years of experience as a venture capitalist since 1987.

Prior to establishing AZCA in 1985, Mr. ISHII was a senior management consultant at McKinsey & Company, Inc., where he planned and managed projects for numerous corporations in Japan, Europe and the United States, focusing on international diversification strategies.  He was an active member of the firm’s Technology Practice and Electronics Practice.  He was also instrumental in developing the firm’s Pacific Rim Practice in providing East-West links for companies entering new markets and establishing businesses on both sides of the Pacific.

Before joining McKinsey, Mr. ISHII was an influential contributor in the computer industry for more than a decade, including eight years with IBM in Japan.  While at IBM, Mr. ISHII was involved in a broad range of technical and management activities, and co-authored two books on IBM’s database and data communications architecture.

Mr. ISHII serves on the board and the advisory board of several multinational companies.  He was a Senior Executive Advisor to PARC (Palo Alto Research Center), a Xerox company, until 2012.  He also serves or has served on the board of various associations, including the Japan Society of Northern California and the Japanese Chamber of Commerce in Northern California (President in 2007).  He was also a member of the US-Japan Innovation and Entrepreneurship Council that was concluded in late 2012.

He is a frequent speaker and writer on issues involving innovation and entrepreneurship as well as international corporate development, and is a well-recognized member of the Pacific Rim business infrastructure.  He is a visiting professor at Waseda University Business School and at Graduate School of Engineering, Shizuoka University. 

Mr. ISHII holds a Bachelor of Engineering in mathematical engineering and instrumentation physics from the University of Tokyo and a Master of Science in computer science from Stanford University.

[ Back to top ]

Yue-Teh Jang
Chairman & CEO, Medeon Biodesign, Inc.

Dr. Jang is currently the Chairman and CEO of Medeon Biodesign, a Taiwan publically traded medical device company with its headquarters in Taipei, Taiwan and a subsidiary in Los Altos, CA. Medeon Biodesign’s business includes medical device incubation, development and manufacturing, as well as investment in startups and late stage companies. When investing in US medical device companies, Medeon Biodesign provides its portfolio companies with development and manufacturing supports from the Taiwan infrastructure.  In addition, the portfolio companies enjoy Medeon Biodesign’s connection to the funding sources in Taiwan for capital needs.

Dr. Jang spent the last 13 years as general partner of The Vertical Group and has more than 30 years of experience in various executive positions in the healthcare industry. He was President and Chief Executive Officer of Embol-X, Ensure Medical, Integrated Vascular Systems, and Kyphon. Prior to that time, Dr. Jang was vice-president for corporate R&D at Boston Scientific, vice-president for R&D at Cardiovascular Imaging Systems, a project manager with Mallinckrodt Medical, and a scientist with Deseret Medical. He currently serves on the Boards of Directors of Tricorntech, iXensor, and Panther Orthopedics. Dr. Jang received a B.S. in Materials Science from National Tsing-Hua University, Taiwan and a Ph.D. in Materials Science from the University of Utah.

[ Back to top ]

Kewen Jin
Partner, Serica Partners

Kewen Jin is a serial entrepreneur in China with an extensive background at U.S.-based venture capital and pharmaceutical companies.

He is the CEO and co-founder of Symap Medical, a medical device company based in China. He is also chairman of BayHelix, an organization of Chinese life-sciences business leaders in China and the U.S., and a special advisor to the Bill & Melinda Gates Foundation in its China R&D matters. In the last 15 years, Jin co-founded and served as CEO of several companies in the areas of drug discovery, medical devices, healthcare services and contract research organizations. He has been an advisor to many pharmaceutical, healthcare companies, consulting and investment firms.

Jin also helped two leading life-science parks in China – Shanghai Zhangjiang and Suzhou Biobay – to develop and implement strategic plans, and was the founding chair of the Shanghai CRO Association. Previously, he was a marketing and international operations executive with Wyeth in the U.S. and in China. Jin studied medicine at the Shanghai Jiaotong University School of Medicine, molecular biology at Rockefeller University and finance at Columbia University.

[ Back to top ]

Kevin M. King
President & CEO, iRhythm Technologies, Inc.

Kevin M. King has served as iRhythm’s President, Chief Executive Officer and a member of the board of directors since July 2012. Mr. King has nearly three decades of experience in the healthcare and IT industries in leadership roles. Previously, he was President, Chief Executive Officer of Affymetrix, Inc., a publicly traded technology innovator in the field of genetic analysis. Prior to that, he served as President and Chief Executive Officer of Thomson Healthcare, an information services business which focused on a range of healthcare-related businesses. Mr. King was also a senior executive at GE Healthcare and began his career at HP’s Medical Products Group.

[ Back to top ]

Amy Len Kobe
Director, Baxter Ventures

Amy Len Kobe is a Director with Baxter Ventures. Baxter Ventures is the corporate strategic venture arm of Baxter International and invests in innovative technologies, products and therapies that have the potential to accelerate growth for the organization as well as advance our mission of saving and sustaining lives. Prior to Baxter, Amy was a digital health investor with Healthbox, a platform for innovation and growth in healthcare and one of the first business accelerators in the industry. Amy began her career in biotech manufacturing and regulatory and was also a management consultant with McKinsey and Company. Amy has degrees in Chemical Engineering from Stanford University and an MBA from the Kellogg School of Management.

[ Back to top ]

Jeffie Kopczynski
Principal Patent Counsel, Medtronic

Jeffie Kopczynski is Principal Patent Counsel in the Cardiovascular Group at Medtronic. At Medtronic, Ms. Kopczynski has counseled and worked on a variety of IP-related matters, including licensing, US and international patent invalidation challenges, patent litigation, patent portfolio management, due diligence, and trademark registrations and oppositions.

Prior to joining Medtronic in 2011, Ms. Kopczynski practiced patent law in the Medical Device Group at Morrison & Foerster's Palo Alto office, and began her legal career at Fish & Richardson's Boston office. In both roles, Ms. Kopczynski worked on IP for numerous types of medical technologies, representing start-up companies, public companies and investors.

Ms. Kopczynski is originally from the Bay Area, and graduated with an A.B. in Chemistry from Princeton University and a J.D. from Harvard Law School.

[ Back to top ]

Anne Kopf-Sill
Licensing Associate, Stanford University

Anne Kopf-Sill is a Licensing Associate with the Stanford Office of Technology Licensing (OTL).  She has a scientific background with a PhD in Chemical Engineering from Stanford University and business experience at Molecular Devices, Abaxis, Caliper, NuGEN, CellPoint Diagnostics and Tecan.  Her responsibilities at OTL focus on Biotechnology and Physical Sciences.

[ Back to top ]

Jennifer Kozak
Vice President, Business Development, Johnson & Johnson

Jennifer Kozak is Vice President, Business Development in Johnson & Johnson’s Medical Devices group. In this role, Jennifer is responsible for Business Development (BD) activities for New Growth Platforms. She also works to develop and lead new external innovation models and works with Johnson & Johnson Development Corporation to optimize our equity investment strategy and portfolio. Jennifer has led numerous BD projects and strategic assessments, including the strategy to enter the ENT (Ears, Nose, Throat) space leading to the acquisition of Acclarent, and the Angiotech knotless tissue closure device asset acquisition. She began her career at Johnson & Johnson as an engineer at Johnson & Johnson Interventional Systems prior to the merger with Cordis Corporation. While at Cordis, she held various roles in Operations, R&D and New Business Development. Following Cordis, she joined Ethicon, Inc. a Johnson & Johnson company in New Business Development responsible for New Growth Opportunities. Jennifer has a BS in Chemical Engineering from Bucknell University, and completed the Smith College Leadership Consortium Executive Education.

[ Back to top ]

Uday Kumar
Founder, President & CEO, Element Science

Dr. Uday N. Kumar, a cardiologist and cardiac electrophysiologist (EP) by training, is the Founder, President and CEO of Element Science, Inc., a venture-backed company funded by Third Rock Ventures and Google Ventures that is developing an innovative device for the treatment of sudden cardiac death. Prior to this, he was an Entrepreneur-in-Residence at Third Rock Ventures, where he focused on leading the development of new medical technologies. Uday is also the Founder of iRhythm Technologies, Inc. (NASDAQ: IRTC), a digital health company that develops cost-effective devices and systems for cardiac rhythm monitoring. He served as a Board member and Chief Medical Officer of iRhythm from founding through commercialization of its Zio® Patch cardiac monitoring device. Uday also Co-founded and serves as a Board Member of Qurious.io, Inc. and is a Board Member of G-Tech Medical, Inc.

He also serves as an Adjunct Professor of Bioengineering at Stanford University where he is the Director of Strategy for the Biodesign Program and Fellowship Director of the Global Biodesign Programs. Uday was a Biodesign fellow at Stanford, a cardiac EP and cardiology fellow at the University of California, San Francisco (UCSF), and an internal medicine resident at the Columbia-Presbyterian Hospital of Columbia University. Prior to his training, Uday was Vice-President and Chief Medical Officer of Biomedical Modeling Inc., a start-up company that created rapid prototyping models from imaging data for use in numerous medical applications. Uday received his M.D. and B.A. (magna cum laude in Biochemistry) from Harvard University.

[ Back to top ]

Mark Leahey
President & CEO, Medical Device Manufacturers Association (MDMA)

Mark Leahey is the President and CEO for the Medical Device Manufacturers Association (MDMA), a national trade association in Washington, DC that represents hundreds of research-driven medical technology companies. Michael's responsibilities include advocating on behalf of the entrepreneurial sector of the medical device industry to Congress, the Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS), and other federal and state agencies. He has lobbied for a more reasonable user fee for smaller companies, worked to open access to the hospital marketplace by challenging the exclusionary and anti-competitive nature of certain large group purchasing organizations (GPOs), as well as ensure that medical device technologies are reimbursed adequately. Michael has been named one of the medical device industry's top lobbyists and sits on the Editorial Advisory Board of Medical Product Outsourcing. He is a member of the Massachusetts Bar and a graduate of Georgetown University, the Georgetown Law Center and Georgetown's McDonough School of Business.

[ Back to top ]

Christopher Letang
Managing Director, SRS Acquiom

Chris is the Managing Director of SRS Acquiom LLC's Professional Services team. He and his team work to resolve claims against escrow funds, purchase price adjustments, and disputes about contingent consideration owed in M&A transactions. Shareholders have been saved over $450 million in contested escrow claims—a return of over 20x on the fees charged—as the result of Chris and his team's work.  His team also manages the process by which post-closing merger proceeds are distributed to shareholders as well as the wind-down and liquidation of any entities remaining after an M&A deal is completed.  In 2015, Chris was recognized in the Service Provider category of The M&A Advisor's 6th Annual 40 Under 40 Emerging Leaders Awards.

Before joining SRS Acquiom, Chris practiced corporate law in the Colorado office of Cooley LLP, where he focused on venture capital transactions and mergers and acquisitions. He began his legal career at Cravath, Swaine & Moore LLP in New York City. At Cravath, he primarily represented underwriters in initial public offerings and high-yield debt offerings and lenders in commercial banking transactions.

Chris holds a J.D. from Harvard Law School and a B.A. from Rice University.

[ Back to top ]

Angela Macfarlane
Managing Member, ForSight Labs

As a Managing Member of ForSight Labs, Ms. Macfarlane brings broad experience in early stage company formation to create a community of innovation where creative solutions and “the doing” are combined to spin out companies and build value focused on improving the lives of visually impaired patients. Over the past ten years, ForSight has started six VISION companies, which have collectively raised over $150M -- including
Transcend Medical, Inc. – Acquired by ALCON/Novartis, ForSight Newco II, Inc. – Acquired by QLT, NexisVision – Licensed to a strategic partner, and ForSight VISION5, Inc. – Acquired by ALLERGAN. Ms. Macfarlane served as CEO for ForSight VISION5, Inc., and currently serves as President and CEO of ForSight VISION4, Inc., a company revolutionizing how drugs are delivered to treat retinal diseases, recently acquired by Roche Holdings US. Forsight VISION6, Inc. is an ongoing development stage company operating under a strategic partnership.

Prior to joining the ForSight Labs team full-time, Ms. Macfarlane served as Chief Technology Counsel to The Foundry, a Medtech incubator. Ms. Macfarlane’s previous experience also includes serving as Technology Counsel for Thomas J. Fogarty, M.D., a renowned physician/entrepreneur, where she participated in all aspects of early stage technology review, licensing, intellectual property management and company creation. She has served as part of the senior management team and in-house counsel at several medical device start-up companies, including TransVascular, Inc. (acquired by Medtronic), AneuRx, Inc. (acquired by Medtronic), and VidaMed Inc. (through IPO).

Ms. Macfarlane is a member of the Advisory Committee to USIJ (usij.org) focused on preserving the U.S. ecosystem for innovation, and serves on the board of Forsight VISION6, Inc. Ms. Macfarlane is an inventor on 25 U.S. issued patents with others currently pending. She received her BA in Business Administration from San Francisco State University, and her J.D. from Golden Gate University School of Law.

[ Back to top ]

Donald May
Executive Vice President, Payment & Health Care Delivery Policy, AdvaMed

Donald May joined AdvaMed in November 2013 as executive vice president, payment and health care delivery policy. He is responsible for leading AdvaMed’s advocacy efforts on payment and health care delivery policy, and serves as the association’s lead representative on payment, coverage and access issues.

Mr. May plays a key role in shaping AdvaMed’s policy development aimed at guarding against the potential for unintended consequences, such as stinting on care and hindering innovation, while also seeking to preserve what’s good about the new approaches.

Mr. May formerly served as vice president for policy at the American Hospital Association, leading AHA's policy development activities for Medicare and Medicaid payment. In his 12 years at AHA, he helped set policy positions for the association through member outreach and consensus building, supported legislative and regulatory advocacy, and served as an AHA spokesman.

Prior to AHA, May was a senior manager with The Lewin Group, where he provided expert policy analysis and consulting on federal health care legislation, trends in hospital financial performance, Medicaid payment adequacy and community health. He also previously served as a health services policy analyst for the Ohio Medicaid hospital program.

Mr. May most recently was managing director with the Farragut Square Group, where he led FSG’s health care facilities research since September 2012. He has a master of public administration degree from The Ohio State University and a bachelor’s degree in political science from Ohio University.

[ Back to top ]

Casey McGlynn
Partner, Wilson Sonsini Goodrich & Rosati

In 1990 Casey McGlynn formed the Life Sciences Group at Wilson Sonsini Goodrich and Rosati, a nationally recognized leader in the representation of startup and emerging growth companies in the life sciences field. Mr. McGlynn has one of the largest practices in the country focused on Medtech, Mobile Health and Biotech companies.

Mr. McGlynn has formed, represented, sold and taken public many of the most important medical device companies started during the last 25 years.

Mr. McGlynn has extensive hands on experience in helping entrepreneurs form, build, fund and sell their companies. He has formed, participated with the boards of and invested in companies in all of the major Medical Device fields. Over the last 25 years he has built close working relationships with an unparalleled list of entrepreneurs, doctors, investors, engineers, and managers in this industry. Through his portfolio of companies he has met with and negotiated with the leaders of all of the major Medtech acquirers.

Over much of his career, Mr. McGlynn participated in forming and managing several small funds all of which have been top quartile performers. In 2005 Mr McGlynn founded Life Science Angels, an angel organization focused on investing in biotechnology and medical device companies. Since formation, LSA has invested over $30 million in more than 40 companies which have received an additional $600+ million in follow-on funding from VCs.

Mr. McGlynn is a member of the board of directors of the Fogarty Institute for Innovation, the Medical Device Manufacturers Association and was a founding board member of the Emerging Business Committee of BIO.

[ Back to top ]

Eric Milledge
Operating Partner, Endeavor Vision SA

Eric joined Endeavour Vision Ltd in 2009 to work with the team on new Medtech investments and contribute to the development of the portfolio. Eric has been involved in all of the Medtech investments for Endeavour II LP and is currently Chairman of the Board for Symetis and CeQur. Eric also serves as a Board member for DFB Pharmaceuticals and OrthoBond Inc.

Eric has 36 years of experience with Johnson & Johnson having begun his Johnson & Johnson career in 1973 as a sales representative for the company's affiliate Ortho Canada. He advanced through sales and marketing management positions and became a member of the Ortho Canada Management Board in 1981. In 1986 he relocated to the U.S. as national sales manager of Ortho Pharmaceutical Corporation. He then progressed to Vice President, corporate development and Vice President, sales and marketing for Ortho U.S. In 1991, Eric became President of Ortho Pharmaceutical Corporation and in 1993 he was named President for the newly created Ortho-McNeil Pharmaceutical.

Eric was named company Group Chairman for Johnson & Johnson Health Care Systems Inc. in June 1998. Eric was also responsible for LifeScan, Inc. during which time he spent considerable time building the LifeScan business in the Asia Pacific region. He was also a member of the Medical Devices & Diagnostics Group Operating Committee. Throughout his career and through his global leadership roles Eric has spent 17 years traveling to Asia to build and develop healthcare businesses.

Eric has maintained many voluntary positions dedicated to the improvement of healthcare and medical technology, he served on the Board of the Liberty Science Center and the Epilepsy Foundation. He was honoured by the Women's Counselling Center in 1998 and the Women's Resource Center in 1994 and was the recipient of the 1994 Man of the Year award from the Epilepsy Foundation. In 1999, he was honoured as Humanitarian of the Year by the Martin House for Justice Foundation, and in 2002 Eric was honoured as "Father of the Year" by the American Diabetes Association.

Eric received an honorary Doctorate from St. Mary's University in Economics and a B.Com degree from St. Mary's University having previously studied a business studies course at York University, Canada.

[ Back to top ]

Trevor Moody
Managing Director, M.H. Carnegie & Company

Mr. Moody is a Managing Director with MH Carnegie & Co., a leading Australian Private Equity and Venture Capital firm. Mr. Moody is also President of TM strategic Advisors LLC, a management consultancy serving the boards, investors and senior management of both emerging and established medical technology companies.

Mr. Moody brings significant experience with over 25 years in the development, commercialization and funding of innovative, growth-oriented medical technologies. He was most recently a General Partner at Frazier Healthcare Ventures, a leading healthcare venture capital and private equity investment firm with $1.8 billion under management. Mr. Moody co-led the medical device team at Frazier and became known as an active and well-regarded investor.  Prior to Frazier Healthcare, Mr. Moody was a Senior Consultant at The Wilkerson Group.

Mr. Moody graduated from the Massachusetts Institute of Technology with a Masters of Science in Management (Sloan School) and the University of Southern Queensland, Australia with a Bachelor of Engineering. Trained as a Biomedical Engineer with an electrical focus, Mr. Moody held product development and product marketing roles at Telectronics Pacing Systems and Ventritex, both in the cardiac rhythm management market. 

Mr. Moody is Board Chair of Seattle BioMed , one of the largest independent, non-profit research institutes focused on diseases of the developing world. Mr. Moody is also on the Board of Directors of Cardiac Dimensions and ElectroCore Medical.

[ Back to top ]

Jack Moorman
Chairman, US-Japan MedTech Frontiers (USJMF)

Jack Moorman is Chairman of US-Japan Medtech Frontiers, a nonprofit organization. US-Japan Medtech Frontiers organizes conferences and symposia in Japan to promote collaboration between the US and Japan to create and commercialize novel medical devices. Now in its fourth year, USJMF has organized conferences in Sendai, Osaka, Hiroshima, and in 2017 the conference will be in Okinawa. In addition, each year USJMF has organized a symposium for Japanese senior executives held in Tokyo with the support of the US Embassy. USJMF is also a strong supporter of the Japan Biodesign Program, now in its second year.

Jack is also the Principal at LeVaunt, LLC, a consulting firm providing advisory services to companies and organizations, particularly early stage ventures in the fields of healthcare and consumer products. He was also recently honored to be named Visiting Faculty Member, Graduate School of Medicine, Osaka University.

With an undergraduate degree in Engineering from the University of Illinois, Jack initially worked in the semiconductor industry leading groups in packaging, testing, assembly, and military products. Jack was the first employee sponsored by Intel to attend the prestigious Stanford Business School Sloan Program where he received an MS in Management. On returning to Intel after the program, he transferred into the semiconductor equipment side of the business and after assignments in manufacturing, field service and marketing moved to Fairchild Test Systems where he became Director of Engineering. After Fairchild he spent five years as founder and director at GenRad Semiconductor Test, Inc. Subsequently Jack was hired by Nanometrics, Inc., public company, where he was promoted to President. Following Nanometrics, Jack did company turn-arounds in semiconductor equipment, medical devices, and in LCD manufacturing equipment. In 1992 Jack founded Cardiac Mariners where he was co-inventor of the technology for a novel x-ray system. In 1999, he founded MCT Medical which was merged with Vivant Medical and where he was CEO and co-inventor of their microwave ablation technology. Vivant was later sold to Tyco.

Jack has been involved in a wide array of companies, technology, and products. In addition to a turn-around in a semiconductor equipment company and Board membership at one of the largest U.S. providers of skilled nursing and assisted living, he has consulted with a Russian investment group on fiber lasers, a Chinese company supplying polyurethane materials, a ski equipment company, a company supplying consumer products to big box stores, Japanese companies looking for medical device acquisitions, consulted with two orthopedics robotic companies, and developed a novel device for sentinel lymph node biopsy and assisting Japanese companies in developing innovative medical devices. To date, he has fourteen issued U.S. patents. 

[ Back to top ]

Yuichiro Morimoto
Vice President, Chief Business Strategy and Innovation Office, Enplas

Yuichiro leads multiple global teams in the SF Bay Area, New York City, Cambridge UK, Haifa Israel, and Tokyo to generate new businesses through M&A, venture investment, and organic R&D, by leveraging Enplas’ ultra-precision polymer manufacturing technologies. The teams cover various industries such as in-vitro diagnosis, medical devices, optical components, automotive, and consumer electronics. His teams provide hands-on support to its portfolio of companies through its many years of expertise in precision manufacturing, global supplier management, sales process and distribution, business development, and fund raising. Yuichiro is on the board member of many of the companies Enplas has invested in.

Prior to joining Enplas, Yuichiro worked for McKinsey for 10 years supporting Japanese and global companies in medical device, pharmaceutical, automotive, and consumer electronics industries. Yuichiro holds a Ph. D. in nuclear engineering from the University of Tokyo.

[ Back to top ]

Scott Murano
Partner, Wilson Sonsini Goodrich & Rosati

Scott Murano is a corporate and securities partner in Wilson Sonsini Goodrich & Rosati's Palo Alto office. Scott advises companies on general corporate matters, including formation and operation, corporate governance, intellectual property and licensing, and employment-related matters. He also has assisted companies in numerous capital raising transactions, including early- and later-stage venture capital financings, debt financings, and public offerings. In addition, Scott advises companies on transactional matters and has worked on a number of merger and acquisition transactions, including public and private company mergers and acquisitions and joint ventures. Scott's experience with venture capital financings and public offerings includes representation of venture capital firms.

[ Back to top ]

Reza Naima
Founder & CEO, ReThink Medical

Reza Naima, Ph.D. is the founder and CEO of Rethink Medical, Inc. The company has developed a wrist worn wearable medical device capable of predicting when heart failure patients are at high risk for hospitalization, thus enabling proactive interventions capable of significantly reducing hospitalizations.

[ Back to top ]

Sara Nakashima
Senior Licensing Associate, Stanford University

Sara Nakashima is a Senior Licensing Associate in Stanford’s Office of Technology Licensing, where she handles a portfolio of life science and medtech inventions. At Stanford OTL, Sara is responsible for the evaluation, marketing, patent strategy, licensing and maintenance of over 300 inventions. She is a Certified Licensing Professional and has a B.S. in biological sciences from Stanford.

[ Back to top ]

Evan Norton
Divisional Vice President, Abbott Ventures, Inc.

Evan Norton is Divisional Vice President and leads Abbott Ventures (AVI) based in Abbott Park, Illinois.  He joined AVI in 2010 and took over primary responsibility for managing all of the investment activities of the group in 2012.  He is also an adjunct professor at Northwestern University where he teaches Medical Device Commercialization and Funding.  Previously, he was a Principal with ONSET Ventures focused on medical technology investing.  He has a diverse background of operating experience in medical technology including the endoscopy, diabetes and ear, nose and throat markets having worked for Stryker Endoscopy, J&J LifeScan and Acclarent.

In addition to his medical device experience, Evan worked for Compaq Computer Corporation's Strategic Investments group, the Investment Banking Group at J.P. Morgan Chase & Co and in the consulting practice at PriceWaterhouseCoopers.

Evan holds an MBA degree from the J.L. Kellogg Graduate School of Management and a BBA in Finance from Texas A&M University.  At Northwestern, he currently serves on the Innovation and New Ventures Advisory Board (Office of Technology Transfer), the N.XT Venture fund advisory board, and the NUVention Medical advisory board.

[ Back to top ]

Philip Oettinger
Partner, Wilson Sonsini Goodrich & Rosati

Philip Oettinger is a partner in the life sciences practice at Wilson Sonsini Goodrich & Rosati, where he focuses primarily on medical device, biotechnology, pharmaceutical, diagnostic, and digital health companies. His practice involves assisting private and public companies with corporate governance, initial public offerings, mergers and acquisitions, public company reporting, and private equity and debt financings. He routinely works with incubators on structuring matters and balancing their rights with those of the companies they are forming. Philip serves as co-chair of the Finance Committee and a member of the Compensation Committee. From 1995 until 2000, Philip was with the Securities and Exchange Commission in Washington, D.C., where he inspected stock exchanges, worked on corporate finance matters, led enforcement investigations, and served as special counsel to Commissioner Laura S. Unger.

[ Back to top ]

Richard "Rick" Packer
Primary Executive Officer, Leader of Global Health Care Business Unit, Asahi Kasei Corporation;
Chairman, ZOLL Medical Corporation

Mr. Packer joined ZOLL Medical Corporation in 1992 as Vice President of Operations, becoming Chief Executive Officer (CEO) in 1996, then Chairman of the Board of Directors and CEO three years later. Mr. Packer continued as CEO through ZOLL’s acquisition by Asahi Kasei in April 2012, through March of 2016. On April 1, 2016, he assumed the new role of Primary Executive Officer of Asahi Kasei, leading the corporation’s global Health Care Business Unit, made up of Asahi Kasei Pharma, Asahi Kasei Medical, ZOLL, and future health care companies. He continues to serve as the non-executive Chairman of ZOLL.

Before joining ZOLL, Mr. Packer was employed as vice president of various functions for Whistler Corporation, a consumer electronics company, from 1987 to 1992. Prior to this, he was a manager with the consulting firm of PRTM/KPMG, specializing in the operations of high technology companies.  Mr. Packer received his bachelor and master degrees in engineering from Rensselaer Polytechnic Institute and an MBA from Harvard Business School.  

Since April 2007, Mr. Packer has served as a director of Bruker Corporation, a scientific instruments company.  He is currently on their audit committee.

[ Back to top ]

Jenell Paul-Robinson
MSN, RN, Vice President, Clinical Value and Provider Relations, MedTech Innovator

Jenell Paul-Robinson, MSN, RN is Vice President, Clinical Value and Provider Relations at MedTech Innovator. She received her master’s degree in Nursing Administration from UCLA.

Jenell brings over 20 years clinical, operational, and administrative expertise to the MedTech Innovator team.  Her specialties include critical care nursing, strategic sourcing, and hospital organization value analysis experience.  Prior to joining MedTech Innovator, Jenell served as the value analysis coordinator for UCLA Health.  Jenell served on several national supply chain and academic medical center value analysis professional committees, charged with evaluating emerging technologies and supply chain initiatives for GPO member consideration.

[ Back to top ]

Donna Petkanics
Partner, Wilson Sonsini Goodrich & Rosati

Donna Petkanics is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. Her law practice focuses on the representation of growth companies, with a particular emphasis on corporate and securities issues. She represents both privately held and public companies across a broad range of industries, including telecommunications, Internet infrastructure, networking, life sciences, computer software and hardware, clean technology and energy, and electronics. She has experience representing companies in many types of corporate transactions, including mergers and acquisitions, initial public offerings, and joint ventures. She also counsels clients who are starting new businesses with respect to general corporate matters and protection of their intellectual property.

During her tenure at the firm, Donna has served in a number of management positions, including managing director of operations and chair of the Operations Committee from 2000 to 2006; member of the firm's board of directors and Policy Committee; chair of the Compensation Committee; associate managing partner of the firm; and co-chair of the Hiring Committee and Nominating Committee. She served on the board of directors of the Wilson Sonsini Goodrich & Rosati Foundation from 2000 to 2010.

Prior to attending law school, Donna was a staff economist in the Executive Office of the President during Jimmy Carter's administration and also worked for the House of Representatives. She began practicing at Wilson Sonsini Goodrich & Rosati in 1985.

[ Back to top ]

Doug Portnow
Partner, Wilson Sonsini Goodrich & Rosati

Doug Portnow is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he focuses his practice on patent prosecution and counseling. He regularly works with inventors to prepare new patent applications, and to draft amendments in response to office actions from the U.S. Patent and Trademark Office. Doug is also experienced in patentability, validity, and freedom-to-operate studies. He has worked extensively in the medical device and surgical sectors, including interventional cardiology, vascular surgery, and orthopedics, as well as with more traditional mechanical inventions.

Doug has worked actively with a number of start-up companies to help develop their intellectual property portfolios as well. He has performed due diligence work for numerous clients during venture financing and M&A activities, with many of these companies successfully raising capital or being acquired by public companies.

Prior to joining the firm, Doug was an associate in the mechanical and medical device group at Townsend and Townsend and Crew LLP (now Kilpatrick Townsend & Stockton). Before entering the legal profession, he worked for more than a decade in the medical device industry. He also held positions in engineering and senior management at start-up companies and well-established medical manufacturers located both within the U.S. and overseas.

[ Back to top ]

Praveen Raja
Amgen Strategy & Innovation

Praveen is currently with Amgen Strategy & Innovation focused on developing partnerships encompassing medical devices, diagnostics and digital health.  Praveen has extensive experience in the development and commercialization of innovative medical devices, diagnostics, pharmaceuticals and digital health at both start-up companies and large global corporations that have achieved clinical adoption and commercial success globally.   Prior to Amgen, Praveen served as the VP of Medical Science and Solutions at Proteus Digital Health, a company focused on developing and commercializing digital medicines (ingestible sensors integrated with medications, wearable sensors, mobile apps and analytics) in a broad range of therapeutic areas.  Prior to Proteus, Praveen led clinical development and medical affairs at Johnson & Johnson Medical Device & Diagnostics focused on blood glucose monitoring and diabetes solutions for global markets.  Prior to his industry positions, Praveen was the Chief of Behavioral Medicine at Kaiser Permanente.  Praveen's academic background includes a Ph.D. from UCLA where he also completed training in clinical psychology and behavioral medicine.   In addition to his formal positions, Praveen has entrepreneurial experience as co-founder of a cloud-based medical software company.

[ Back to top ]

Leighton Read
Venture Partner, Brandon Capital Partners

Leighton, is based in Silicon Valley and helps Brandon portfolio companies integrate into the financing and commercialisation ecosystem of US life science sector.

Leighton is an American serial entrepreneur and venture investor with a long track record of building companies that have commercialized important medicines and life-science technologies.  From 2000 – 2008 he was a managing director of Alloy Ventures, an early-stage firm investing in life science and technology companies and he continues to look after his remaining portfolio companies as a Venture Partner.

Previously, he founded Affymax NV (with Alejandro Zaffaroni) where he served as Managing Director and President of the Pharma Division, sold to Glaxo SmithKline and spun out Affymetrix and Maxygen.  He was the founding investor, Chairman and CEO of Aviron which developed FluMist™, the intranasal influenza vaccine acquired by MedImmune.  Leighton has been a director of companies ranging from biotechnology, medical devices, materials science, energy and software.  His current portfolio companies are Alexza, AnaptysBio, Cambrios, Genomatica, Siluria and Synergy Eyes.

Leighton received a B.S. from Rice University in Houston in Psychology and Biology, an MD from the University of Texas Health Science Center at San Antonio, and completed internal medicine training at Duke and the Peter Bent Brigham Hospital, where he held appointments at the Harvard Medical School and School of Public Health.  His research dealt with applications of decision theory in medicine and policy regarding medical innovation.  He produced a successful interactive game in 1984 to promote healthy lifestyles and carried this interest to his current role as Co-founder of Seriosity and co-authored (with Byron Reeves) Total Engagement: Using Games and Virtual Worlds to Change the Way People Work and Businesses Compete.

Leighton serves as a trustee or director of The BeneTech Initiative, BioVentures for Global Health, The UC Berkeley Foundation and School of Public Health Council, and is Vice Chairman of the Santa Fe Institute.  His awards include several as co-inventor of technology underlying the Affymetrix GeneChip™ and Ernst & Young's Northern California Life Science Entrepreneur of the Year.

[ Back to top ]

Duke Rohlen
CEO, Spirox, Inc.

Duke has over 15 years of experience as an executive in medical device companies.  He currently serves as CEO and Director of Ajax Health, co-founder and CEO of Spirox, Inc., and as CEO and Chairman of Advanced Cardiac Therapeutics. Prior to Advanced Cardiac Therapeutics, Duke served as founder and CEO of CV Ingenuity and President of FoxHollow Technologies.  Duke began his career in healthcare at the private equity firm Alta Partners, where he served as an entrepreneur-in-residence.  Mr. Rohlen received an M.B.A. from Harvard Business School and a B.A. from Stanford University.

[ Back to top ]

Elton Satusky
Partner, Wilson Sonsini Goodrich & Rosati

Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. He specializes in public and private corporate finance and corporate law and governance. Elton also has considerable expertise in the areas of mergers and acquisitions and venture capital.

 

[ Back to top ]

Valeska Schroeder
Managing Director, KCK Group

Valeska Schroeder is a Managing Director of KCK’s Medtech Investment Group. KCK is a family investment fund that invests in a diverse set of industries, including medical technologies. KCK has interests in Life Sciences - Biopharm/ Biotech & MedTech, Energy, Science-rich companies and Industrial Technologies. KCK invests at all stages of a startup's lifecycle from early stage to growth rounds and also invest in public companies. KCK is the private equity arm of a family office which seeks to partner with experienced management teams, focused on niche markets, deploying long-term flexible capital to generate high risk-adjusted returns.

[ Back to top ]

Daniel Sheehan
Director, Medtronic

Dan Sheehan manages the activities of Medtronic / Covidien Ventures. Dan is passionate about working with the managers of entrepreneurial companies and understands the complexity of commercializing new medical technologies. His background includes both venture capital investing and operating company management roles in the healthcare sector. Prior to Covidien, Dan was a General Partner with Affinity Capital Management, a healthcare oriented venture capital firm in Minneapolis. He has also managed the business development and strategic marketing efforts for Steris Corporation, a provider of infection prevention and surgical support products for the healthcare and life sciences sectors. He has been a member of the Board of Directors of many portfolio companies. He is a graduate of Fordham University and Columbia Business School.

[ Back to top ]

John Shimmick
Partner, Wilson Sonsini Goodrich & Rosati

John Shimmick is a registered patent attorney in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where his practice focuses on patent prosecution and counseling designed to help his clients protect their intellectual property rights both domestically and internationally. He regularly works with his clients to conduct patentability, freedom-to-operate, and patent validity analyses, and he also prepares and prosecutes patent applications. John has experience with appeals, reexaminations, litigation support, and opposition proceedings. In addition to protecting intellectual property rights, John has experience with investor due diligence and financing. He frequently advises clients in connection with various rounds of financing, acquisitions and IPOs.

John has a broad technical background and has worked as a patent attorney in several technical fields, including software, optical systems, mechanical devices, laser ablation systems, telemetry, semiconductor manufacturing, and test equipment. He has worked extensively in the medical device sector, including medical instrumentation, implantable devices, healthcare information technology, surgical robotics, tissue ablation systems, medical imaging, hearing devices, ophthalmology, orthopedics, cardiology and orthodontics. Prior to joining the firm, John was an associate in the medical device group at Townsend and Townsend and Crew LLP (now Kilpatrick Townsend & Stockton). He was a patent agent prior to entering law school.

Before entering the legal profession, John worked for more than a decade in the medical device industry, holding positions in engineering and management. While at VISX Inc., John developed laser delivery systems and ablation algorithms and was involved intimately with the evolution of LASIK, from blind-eye studies to FDA-approved wavefront guided LASIK. This work led to the successful treatment of millions of eyes, and John is the named inventor or co-inventor on over 40 issued patents worldwide. His background of successful engineering and intellectual property law gives him a unique perspective and ability to work with clients.

[ Back to top ]

2Sarah Sorrel
Founder & President, Medpass International

Sarah Sorrel has more than 30 years of experience in medical device clinical trials and regulatory affairs in Europe and the US.

As founder and President of MedPass International SAS, Sarah has been a pioneer by developing the first European CRO exclusively devoted to medical devices. Leading a team of clinical research and regulatory experts, Sarah has helped over 1000 companies bring novel medical devices to the EU market.

Formerly having served as part of the startup team at Technomed International (now part of Siemens), Sarah brought her experience to bear at MedPass International where she has helped numerous startups develop devices that were first in their category leading to rapid acquisition by major industry players.

A recognized expert in clinical investigations of medical devices, Sarah represented AFNOR at CEN/TC258 for the development of standard EN/ISO 14155. She is a member of RAPS and a faculty member for the Society’s conferences. As President of MedPass International Limited, Sarah is a founding member of the European Association of Authorized Representatives. Sarah, an American, holds a French Baccalaureate with honors, a B.S. in Chemistry and an M.S. from the Becton School of Engineering and Applied Science at Yale University.

[ Back to top ]

2Arthur Taylor
Formerly Chairman, Transcend Medical, Inc.

Arthur (Art) Taylor is President and CEO of Monterey Advisors. Art was most recently President & CEO of PhotoThera, Inc., a clinical stage medical device company whose platform technology uses non-invasive near-infrared laser energy to treat a broad range of neurological diseases. Prior to that, he served as VP and General Manager for the Kyphon Spinal & Biologics Business of Medtronic following Medtronic's acquisition of Kyphon, Inc., and as Kyphon's COO and CFO prior to the acquisition. Prior to Kyphon, Art gained in-depth experience across the healthcare industry while serving as CFO for ReSound Corporation, a hearing healthcare company, and in executive positions with Allergan, Inc. and American Hospital Supply Corporation. Art serves on the Board of Directors of four private medical device companies and holds an MBA from the University of Southern California and a BS in Corporate Finance from San Diego State University.

[ Back to top ]

2Fred Toney
CEO & Co-Founder, Launchpad Digital Health

Fred is CEO & Co-Founder of Launchpad Digital Health, an early-stage seed investor and accelerator for digital health companies, with 16 portfolio companies to date.  He has 20+ years in the technology, medical and digital health markets: Co-Founder, Chairman & CFO of RxList (sold to WebMD); CEO of HealthCentral at its sale and CFO at its IPO on Nasdaq; EVP & CFO of C8 MediSensors which received regulatory approvals of its medical device + medical software application in 27 EU countries. 15+ years in research, investment banking, portfolio management with 100+ companies funded or sold.

[ Back to top ]

2Gwen Watanabe
Vice President, Global Corporate Development and Strategy, Teleflex Inc.

Gwen Watanabe is the Vice President of Global Corporate Development & Strategy and member of the Executive Committee at Teleflex Incorporated. She recently led the $1B acquisition of Vascular Solutions which closed in mid-February of this year. 

Watanabe joined Teleflex in July of 2012 as the Vice President of Hotspur – Cardiac Care through the acquisition of Hotspur Technologies, Inc. At Hotspur, she served as the President & CEO since March 2009.

Prior to joining Teleflex, Watanabe worked in the medical device industry for more than 18 years. Watanabe was a founding leader in three medical device start-ups: AneuRx (acquired by Medtronic); Bacchus Vascular (acquired by Covidien); and Nellix Endovascular (acquired by Endologix).

Watanabe held prior responsibilities within the private equity sector, specifically in medical device venture capital, and she has served on several privately held medical device company Board of Directors.

Watanabe holds a MBA from Harvard Business School, M.S Mechanical Engineering in the BioMechanics Design from Stanford University, and a B.S. Mechanical Engineering from the Massachusetts Institute of Technology.

She is based in Teleflex corporate headquarters in Wayne, Pennsylvania.

[ Back to top ]

2Martin Waters
Partner, Wilson Sonsini Goodrich & Rosati

Martin (Marty) Waters is a corporate and securities partner in the San Diego office and a former member of the firm's Policy Committee. He is a founding partner of the firm's San Diego office and Southern California corporate practice. He was a partner in the Palo Alto office until opening the San Diego office in 2004.

Marty is a proven company builder with nearly 20 years of experience providing corporate and securities counsel. He has been instrumental in starting, building, and shepherding through initial public offering or sale of numerous emerging growth companies in a broad range of industries, including biotech, clean technology, cloud computing, e-commerce, medical device, new and traditional media, SaaS, semiconductors, social networking, and telecommunications. A partial list of exited emerging growth clients includes Ablation Frontiers, CoreValve, Cytokinetics, evite, eyeonics, Helixis, Heritage Pharma, Illumina, Indigo Systems, Lara Networks, N Spine, Optimer Pharmaceuticals, Pain Therapeutics, SKS Microfinance, TearLab, and TweetPhoto. Marty also represents several public companies in a general counsel capacity, as well as investment banks and placement agents in PIPEs and public offerings. Marty has counseled issuers and underwriters in more than 50 offerings while at Wilson Sonsini Goodrich & Rosati and with Cahill Gordon & Reindel and Akin Gump Strauss Hauer & Feld in New York.

Marty's practice is international in reach, but he concentrates on leading the firm's efforts in representing public and private growth companies in San Diego, Orange County, and Los Angeles. He handles a wide variety of complex commercial transactions for clients, including public offerings of equity and debt securities; mergers, acquisitions and divestitures; venture capital financings; and formation and governance of partnerships, strategic alliances, and joint ventures.

[ Back to top ]

Jay Watkins
Managing Director, Curation Capital

Jay Watkins is a Managing Director at Curation Capital. Jay is an operating executive with extensive experience founding and funding healthcare companies including executive management roles at De Novo Ventures, Guidant Corp and Origin MedSystems. He currently serves as Chairman of the Board of Shockwave Medical, Reflexion Medical, and Recor Medical. He also serves as Co-Director of the Biodesign Innovation course at the Stanford Byers Center for Biodesign. Jay received his MBA from Harvard Business School and his undergraduate degree from Stanford University.

[ Back to top ]

Norman Weldon
Managing Director, Partisan Management Group, Inc.

Norm Weldon's background is in economics, technology and general management. He has been the CEO of three public companies: CTS Corporation (NYSE CTS), Cordis Corporation (NASDAQ CORD) and Corvita Corporation (NASDAQ CVTA).  He has been a co-founder of CTS Microelectronics, Inc., Corvita Corporation, Novoste Puerto Rico, Inc., Novoste Corporation, Enable Medical Corporation, AtriCure, Inc., Medivance, Inc., Neuronetics, Inc. and Ponce de Leon, DAC.  Via Partisan Management Group, Inc., Norm has additionally been a seed and early stage investor in HemoCleanse, Inc., Ash Access, Inc., Symbiosis Corporation, Impla-Med, Inc., RxKinetics, Inc., Renal Solutions, Inc., ZS Pharma, Inc., Preceptis Medical, Inc., Surefire Medical, Inc. and Enable Injections, Inc.

Partisan Management Group, Inc. has returned cash on cash results of 6.5 times invested capital over 12 completed investments. Partisan has six current portfolio companies ranging from late stage Neuronetics to very early stage Ponce de Leon. Partisan has also been a limited partner in seven other venture funds.

Norm has degrees in biochemistry, business and a PhD in Economics, all from Purdue University. Norm Weldon and Tom Weldon played roles in the founding and development of what is now known as the Weldon School of Biomedical Engineering at Purdue.

[ Back to top ]